Who is Bifidobacterium infantis suitable for?
Views : 4
Update time : 2026-04-13 14:31:47
Bifidobacterium infantis is a dominant strain in the infant gut. It can efficiently utilize human milk oligosaccharides for preferential colonization and help establish a healthy gut microecology. This bacterium is included in China’s List of Strains Available for Infant and Young Children’s Food. Representative strains include R0033, M-63, YLGB-1496 and others, with clinical evidence supporting its roles in promoting intestinal development, enhancing immunity, and reducing allergy risks.
In terms of application, Bifidobacterium infantis is mainly used in infant formula, probiotic drops, maternal and infant nutritional products, and pediatric special medical foods, supporting early gut microbiota establishment, immune development, and disease prevention.
So who is Bifidobacterium infantis suitable for?Newborns and infants are the primary target population. Clinically, strain M-63 has been shown to reduce early inflammatory levels, YLGB-1496 improves immune homeostasis, and R0033 increases intestinal sIgA levels.Preterm infants supplemented with EVC001 can lower the risk of necrotizing enterocolitis.Pregnant and lactating women can take it to help their offspring establish a healthy microbiota.It is also suitable for children born via cesarean section or after antibiotic use for microbiota reconstruction.
The global market is growing at a compound annual growth rate of approximately 5.8%, and precision-targeted probiotic formulations represent a future trend.
In terms of application, Bifidobacterium infantis is mainly used in infant formula, probiotic drops, maternal and infant nutritional products, and pediatric special medical foods, supporting early gut microbiota establishment, immune development, and disease prevention.
So who is Bifidobacterium infantis suitable for?Newborns and infants are the primary target population. Clinically, strain M-63 has been shown to reduce early inflammatory levels, YLGB-1496 improves immune homeostasis, and R0033 increases intestinal sIgA levels.Preterm infants supplemented with EVC001 can lower the risk of necrotizing enterocolitis.Pregnant and lactating women can take it to help their offspring establish a healthy microbiota.It is also suitable for children born via cesarean section or after antibiotic use for microbiota reconstruction.
The global market is growing at a compound annual growth rate of approximately 5.8%, and precision-targeted probiotic formulations represent a future trend.
